Literature DB >> 21353959

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.

Philippe R S Lagacé-Wiens1, Patricia J Simner, Kevin R Forward, Franil Tailor, Heather J Adam, Melanie Decorby, James Karlowsky, Daryl J Hoban, George G Zhanel.   

Abstract

Escherichia coli was the most commonly isolated pathogen in the Canadian Ward Surveillance Study 2007-2009 (3789 isolates). Susceptibility to cefazolin (34.1%), trimethoprim-sulfamethoxazole (73.8%), ciprofloxacin (78.4%), and levofloxacin (78.8%) was lowest. Susceptibility was above 90% for meropenem (100%), tigecycline (99.9%), piperacillin-tazobactam (97.6%), nitrofurantoin (96.9%), ceftazidime (95.6%), amoxicillin-clavulanate (94.9%), ceftriaxone (94.1%), cefoxitin (92.3%), and gentamicin (90.8%). Over the study period, there was a significant reduction in susceptibility to amoxicillin-clavulanate and trimethoprim-sulfamethoxazole for urinary tract isolates. Inpatient status was associated with greater resistance to nearly all antimicrobials including greater multidrug resistance (MDR). Increasing age was associated with resistance to fluoroquinolones, ceftriaxone, piperacillin-tazobactam, and MDR. Female gender was associated with susceptibility to fluoroquinolones and nitrofurantoin. In conclusion, greater antimicrobial resistance and MDR in E. coli were observed in inpatients, males, and with increasing age. The deterioration of susceptibility to trimethoprim-sulfamethoxazole continues with the greatest reduction in urinary isolates. Significant regional differences in resistance rates were apparent.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353959     DOI: 10.1016/j.diagmicrobio.2010.10.027

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Emergency Department Urinary Antibiograms Differ by Specific Patient Group.

Authors:  S Jorgensen; M Zurayk; S Yeung; J Terry; M Dunn; P Nieberg; A Wong-Beringer
Journal:  J Clin Microbiol       Date:  2017-06-14       Impact factor: 5.948

2.  Comparison of antibiograms developed for inpatients and primary care outpatients.

Authors:  Jessina C McGregor; David T Bearden; John M Townes; Susan E Sharp; Paul N Gorman; Miriam R Elman; Motomi Mori; David H Smith
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 2.803

3.  Prediction of Antibiotic Susceptibility for Urinary Tract Infection in a Hospital Setting.

Authors:  Courtney Hebert; Yuan Gao; Protiva Rahman; Courtney Dewart; Mark Lustberg; Preeti Pancholi; Kurt Stevenson; Nirav S Shah; Erinn M Hade
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  Urinary tract infection in small outpatient children: the influence of age and gender on resistance to oral antimicrobials.

Authors:  Svante Swerkersson; Ulf Jodal; Christina Åhrén; Sverker Hansson
Journal:  Eur J Pediatr       Date:  2014-03-13       Impact factor: 3.183

5.  Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota.

Authors:  Sanjeev K Swami; Juliette T Liesinger; Nilay Shah; Larry M Baddour; Ritu Banerjee
Journal:  Mayo Clin Proc       Date:  2012-07-13       Impact factor: 7.616

6.  Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients.

Authors:  Jessina C McGregor; Miriam R Elman; David T Bearden; David H Smith
Journal:  BMC Fam Pract       Date:  2013-02-22       Impact factor: 2.497

Review 7.  Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.

Authors:  Sajad Yaghoubi; Angelina Olegovna Zekiy; Marcela Krutova; Mehrdad Gholami; Ebrahim Kouhsari; Mohammad Sholeh; Zahra Ghafouri; Farajolah Maleki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-05       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.